

# Omrix Biopharmaceuticals

[View the current Omrix Biopharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32536-Omrix+Biopharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/32536-Omrix+Biopharmaceuticals.html>)

## Contact Details:

**630 5th Avenue, 22nd Floor**

**New York**

**New York**

**10111**

**United States of America**

Tel: 212 887 6500

Fax: 212 887 6550

Email: [info@omrix.com](mailto:info@omrix.com)

We aim to develop novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly in the areas of biosurgical and passive immunotherapy products. We are utilizing our proprietary protein purification technology, innovative development capabilities, and manufacturing know-how to develop these product lines, often through collaborations with companies whose marketing and sales expertise are a complement to our own areas of specialty. Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market, which we believe is the fastest growing segment of the surgical sealant market. We are currently partnered with Ethicon Inc., a Johnson & Johnson Company, in the development of unique biosurgical devices which will meet critical unmet medical needs. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia immunoglobulin, or VIG, to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack. We currently market in Israel intravenous immunoglobulin, or IVIG, an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B immune globulin (HBIG), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.

## Recent Publications by Omrix Biopharmaceuticals:



- [Commercial fibrin sealants are not equivalent in a rabbit liver-resection model which quantitatively evaluates hemostasis and formation of adhesions.](#)  
*A rabbit partial liver resection model was used to determine the...*31st December, 2005  
Omrix Biopharmaceuticals- Eur Surg Res. 2005 May-Jun;37(3):159-65. ([DOI Direct Link](#))
- [The binding of fibrin sealant to collagen is influenced by the method of purification and the cross-linked](#)

[fibrinogen-fibronectin \(heteronectin\) content of the 'fibrinogen' component.](#)

*Two fibrinogen preparations, each an intermediate in the manufacture of...* 8th July, 2005

Omrrix Biopharmaceuticals, Weizmann Science Park, Nes-Ziona, Israel.- Blood Coagulation Fibrinolysis.

2005 Mar;16(2):111-7.

#### Press Releases on Omrix Biopharmaceuticals:

<a href="#">NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company</a>	19th November, 2009	NeoStem, Inc.	<i>NEW YORK, Nov. 19 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS), announced today that it has sent the following letter to its shareholders, discussing the Company's acquisition, on -- U.S. Molecular Diagnostics Markets for Emerging Infectious Disease Tests In the near future, the firm plans to conduct analyses of additional personalized medicine markets: --</i>
<a href="#">Video: Personalized Medicine Drives Multiple Markets, Finds Frost &amp; Sullivan</a>	18th November, 2009	Frost & Sullivan	<i>CALGARY, Nov. 13 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced its third quarter 2009</i>
<a href="#">SemBioSys announces third quarter 2009 financial and operational results</a>	13th November, 2009	SemBioSys Genetics Inc.	<i>MONROVIA, Calif. and HANGZHOU, China, Nov. 13 /PRNewswire-FirstCall/ -- Niusule Biotech Corp. ("Niusule" or the "Company") (OTC Bulletin Board: NIUS), a leading U.S.-based biotech</i>
<a href="#">Niusule Announces Key Additions to Management Team</a>	13th November, 2009	Niusule Biotech Corp.	<i>Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov. 11</i>
<a href="#">AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology</a>	11th November, 2009	AETERNA ZENTARIS INC.	





## Omrix Biopharmaceuticals Patents:

- 7125569- [Removal of plasmin\(ogen\) from protein solutions](#)
- 6113571- [Applicator device for applying a multiple component fluid](#)
- 6121232- [Stabilized mixture comprising fibrinogen](#)
- 6234994- [Multicomponent tissue adhesive application device and holder for such device](#)
- 6357489- [Device for storing a liquid medicinal substance and method for filling an applicator for a liquid medicinal substance by use of said storing device](#)
- 6464663- [Applicator for applying a single--or multicomponent fluid and method for spraying such a fluid](#)
- 6468733- [Method of the inactivation of viruses by a solvent-detergent combination and nanofiltration](#)
- 6565539- [Device for applying a flowable medium, notably a tissue adhesive](#)
- 6568434- [Receiver cup for a vessel housing a medicinal substance](#)
- 6916911- [Use of fibrinogen multimers](#)
- 6019993- [Virus-inactivated 2-component fibrin glue](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

